Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.

Date publication

avril 2018

Journal

The New England journal of medicine

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BARTHELEMY Philippe

Tous les auteurs :
Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthélémy P, Porta C, George S, Powles T, Donskov F, Neiman V, Kollmannsberger CK, Salman P, Gurney H, Hawkins R, Ravaud A, Grimm MO, Bracarda S, Barrios CH, Tomita Y, Castellano D, Rini BI, Chen AC, Mekan S, McHenry MB, Wind-Rotolo M, Doan J, Sharma P, Hammers HJ, Escudier B,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/29562145

Résumé

Nivolumab plus ipilimumab produced objective responses in patients with advanced renal-cell carcinoma in a pilot study. This phase 3 trial compared nivolumab plus ipilimumab with sunitinib for previously untreated clear-cell advanced renal-cell carcinoma.

Mots clés

Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, administration & dosage, Antineoplastic Agents, Immunological, administration & dosage, Antineoplastic Combined Chemotherapy Protocols, adverse effects, Carcinoma, Renal Cell, drug therapy, Disease-Free Survival, Humans, Indoles, administration & dosage, Ipilimumab, administration & dosage, Kidney Neoplasms, drug therapy, Male, Middle Aged, Pyrroles, administration & dosage, Quality of Life, Risk, Survival Analysis, Survival Rate

Référence

N. Engl. J. Med.. 2018 04 5;378(14):1277-1290